The clinical efficacy of targeting these pathways is underscored by the use of anti-TSLP monoclonal antibody, tezepelumab, which showed a substantial, though not statistically significant, improvement in key clinical characteristics of AD, such as the pruritus rating scale (NRS), Investigator’s Global Assessment (IGA), and reductions in both the Eczema Area and Severity Index (EASI) and the SCORing AD index (SCORAD) (122). The gene discussed is TSLP; the disease is Alzheimer disease.